贝伐单抗联合化疗治疗卵巢癌的临床效果

Clinical effect of bevacizumab combined with chemotherapy in the treatment of ovarian cancer

目的探讨贝伐单抗联合化疗治疗卵巢癌的临床效果。方法将我院2017年1月至2018年12月收治的108例卵巢癌患者随机分成对照组(54例,常规化疗治疗)和观察组(54例,贝伐单抗+常规化疗治疗),比较两组的治疗效果。结果治疗后,观察组的治疗总有效率显著高于对照组,CA125、CEA、NSE、IL-4、IL-6及VEGF水平显著低于对照组,QLICP-OV评分显著高于对照组(P<0.05)。结论对卵巢癌患者采用贝伐单抗联合化疗治疗后,能显著降低肿瘤标记物及炎性因子水平,改善生存质量。

Objective To explore clinical effect of bevacizumab combined with chemotherapy in the treatment of ovarian cancer. Methods A total of 108 patients with ovarian cancer treated in our hospital from January 2017 to December 2018 were randomly divided into control group (54 cases, conventional chemotherapy) and observation group (54 cases, bevacizumab and conventional chemotherapy). The therapeutic effects of the two groups were compared. Results After treatment, the total effective rate of treatment in the observation group was significantly higher than that in the control group, the levels of CA125, CEA, NSE, IL-4, IL-6 and VEGF were significantly lower than those in the control group, and the QLICP-OV score was significantly higher than that in the control group (P<0.05). Conclusion Bevacizumab combined with chemotherapy can significantly reduce the level of tumor markers and inflammatory factors, and improve the quality of life in patients with ovarian cancer.